DE69509544T2 - Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten - Google Patents

Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten

Info

Publication number
DE69509544T2
DE69509544T2 DE69509544T DE69509544T DE69509544T2 DE 69509544 T2 DE69509544 T2 DE 69509544T2 DE 69509544 T DE69509544 T DE 69509544T DE 69509544 T DE69509544 T DE 69509544T DE 69509544 T2 DE69509544 T2 DE 69509544T2
Authority
DE
Germany
Prior art keywords
antiprogestin
administration
treatment
gonadotropin
analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69509544T
Other languages
German (de)
English (en)
Other versions
DE69509544D1 (de
Inventor
Daniel Grow
Gary Hodgen
Robert Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastern Virginia Medical School
Original Assignee
Eastern Virginia Medical School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastern Virginia Medical School filed Critical Eastern Virginia Medical School
Publication of DE69509544D1 publication Critical patent/DE69509544D1/de
Application granted granted Critical
Publication of DE69509544T2 publication Critical patent/DE69509544T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69509544T 1994-02-04 1995-02-02 Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten Expired - Fee Related DE69509544T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/191,631 US5681817A (en) 1994-02-04 1994-02-04 Treatment of ovarian estrogen dependent conditions
PCT/US1995/001479 WO1995020972A1 (en) 1994-02-04 1995-02-02 Treatment of ovarian estrogen dependent conditions

Publications (2)

Publication Number Publication Date
DE69509544D1 DE69509544D1 (de) 1999-06-10
DE69509544T2 true DE69509544T2 (de) 1999-09-02

Family

ID=22706258

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69509544T Expired - Fee Related DE69509544T2 (de) 1994-02-04 1995-02-02 Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten

Country Status (29)

Country Link
US (1) US5681817A (show.php)
EP (1) EP0785792B1 (show.php)
JP (1) JP3130048B2 (show.php)
KR (1) KR970700507A (show.php)
CN (1) CN1144486A (show.php)
AP (1) AP724A (show.php)
AT (1) ATE179610T1 (show.php)
AU (1) AU689229B2 (show.php)
BG (1) BG62238B1 (show.php)
BR (1) BR9506606A (show.php)
CA (1) CA2182183C (show.php)
CZ (1) CZ291709B6 (show.php)
DE (1) DE69509544T2 (show.php)
DK (1) DK0785792T3 (show.php)
ES (1) ES2132645T3 (show.php)
FI (1) FI963036L (show.php)
GR (1) GR3030164T3 (show.php)
HU (1) HUT74622A (show.php)
LT (1) LT4182B (show.php)
LV (1) LV11782B (show.php)
MD (1) MD1432C2 (show.php)
NZ (1) NZ281441A (show.php)
OA (1) OA10777A (show.php)
PL (1) PL178273B1 (show.php)
RO (1) RO117420B1 (show.php)
RU (1) RU2110274C1 (show.php)
SK (1) SK96296A3 (show.php)
TJ (1) TJ242B (show.php)
WO (1) WO1995020972A1 (show.php)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003138A1 (en) * 1994-07-22 1996-02-08 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US6274573B1 (en) 1997-10-17 2001-08-14 Mochida Pharmaceutical Co., Ltd. Method of treatment for uterine leiomyoma
US6703367B1 (en) 1999-04-27 2004-03-09 Praecis Pharmaceuticals Inc. Methods for treating hot flashes and gynaecomastia
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US8193252B1 (en) 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
ES2295050T3 (es) * 1999-08-31 2008-04-16 Bayer Schering Pharma Aktiengesellschaft Mesoprogestinas para el tratamiento y la prevencion de trastornos ginecologicos benignos dependientes de hormonas.
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
AU2001295359A1 (en) * 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
US6958142B2 (en) * 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
US6960337B2 (en) * 2002-08-02 2005-11-01 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders
US7029657B2 (en) * 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
EP1865935B1 (en) * 2005-02-17 2011-06-08 Hadasit Medical Research Services and Development Ltd. Bisphosphonates for treating endometriosis
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
TWI455716B (zh) * 2006-10-24 2014-10-11 Repros Therapeutics Inc 選擇性黃體激素受體調節劑用於製造治療雌激素依賴性病症之藥物的用途
MY150763A (en) * 2006-10-24 2014-02-28 Repros Therapeutics Inc Compositions and methods for suppressing endometrial proliferation
WO2008144143A1 (en) * 2007-05-14 2008-11-27 Drugtech Corporation Endometriosis treatment
US20110208118A1 (en) * 2007-09-20 2011-08-25 Bio-Pro Medical Ltd. Compositions and means for treating uterine leiomyomata, leiomyoma, myoma, uterine fibroids, endometriosis, adenomyosis and related disorders by mifepristone
RU2359684C1 (ru) * 2008-01-23 2009-06-27 Закрытое акционерное общество "СКАЙ ЛТД" Способ лечения эндометриоза
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP3560555A1 (en) 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE19975054I2 (de) 1987-08-08 2000-04-13 Akzo Nobel Nv Kontrazeptives Implantat
DE3744054A1 (de) 1987-12-21 1989-06-29 Schering Ag Verwendung von antigestagenen zur herstellung von arzneimitteln
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
EP0472725B1 (en) 1990-03-16 1997-05-21 Applied Research Systems Ars Holding N.V. Treatment of polycystic ovarian disease
US6827050B2 (en) 2001-12-21 2004-12-07 Caterpillar Inc Fluid control valve actuating system
US7283632B2 (en) 2003-09-09 2007-10-16 The Boeing Company Unauthorized access embedded software protection system

Also Published As

Publication number Publication date
BR9506606A (pt) 1997-09-09
CN1144486A (zh) 1997-03-05
LV11782A (lv) 1997-06-20
TJ242B (en) 1999-11-24
FI963036A0 (fi) 1996-08-01
FI963036A7 (fi) 1996-08-01
ES2132645T3 (es) 1999-08-16
SK96296A3 (en) 1997-07-09
OA10777A (en) 2002-12-23
MD1432C2 (ro) 2000-09-30
AU689229B2 (en) 1998-03-26
LT4182B (en) 1997-06-25
DE69509544D1 (de) 1999-06-10
DK0785792T3 (da) 1999-10-18
EP0785792B1 (en) 1999-05-06
RO117420B1 (ro) 2002-03-29
BG62238B1 (bg) 1999-06-30
PL178273B1 (pl) 2000-03-31
BG100766A (bg) 1997-06-30
GR3030164T3 (en) 1999-08-31
MD1432B2 (en) 2000-03-31
CA2182183C (en) 2003-09-16
WO1995020972A1 (en) 1995-08-10
AP9600840A0 (en) 1996-07-31
EP0785792A4 (show.php) 1997-07-30
CA2182183A1 (en) 1995-08-10
US5681817A (en) 1997-10-28
CZ291709B6 (cs) 2003-05-14
EP0785792A1 (en) 1997-07-30
JPH09508418A (ja) 1997-08-26
FI963036L (fi) 1996-08-01
NZ281441A (en) 1999-09-29
RU2110274C1 (ru) 1998-05-10
ATE179610T1 (de) 1999-05-15
LT96133A (en) 1997-01-27
LV11782B (en) 1997-12-20
AU1838695A (en) 1995-08-21
CZ210396A3 (en) 1997-05-14
JP3130048B2 (ja) 2001-01-31
PL315792A1 (en) 1996-12-09
AP724A (en) 1999-01-18
KR970700507A (ko) 1997-02-12
HUT74622A (en) 1997-01-28
HU9601969D0 (en) 1996-09-30

Similar Documents

Publication Publication Date Title
US5681817A (en) Treatment of ovarian estrogen dependent conditions
DE3750764T2 (de) Kontinuierliche verabreichung des luteinisierendes hormon abgebenden hormons in kombination mit sexsteroidverabreichung als empfängnisverhütungsmittel.
DE60216630T2 (de) Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie
EP0723439B1 (de) Kombination von progesteronantagonisten und antiöstrogenen mit partialer agonistischer wirkung für die hormonsubstitutions-therapie für peri- und postmenopausale frauen
DE69532894T2 (de) Verfahren zur empfängnisverhütung
DE60217324T2 (de) Pharmazeutische zusammensetzung für die hormonersatztherapie
DE60223795T2 (de) Tetrahydroxyliertes Östrogen enthaltendes Arzneistoffverabreichungssystem zur Verwendung in der hormonalen Kontrazeption
DE69327319T2 (de) Minimierung von mit progesteron verbundenen durchbruckblutungen
WO1996019997A1 (de) Progesteronantagonistisch- und antiöstrogen wirksame verbindungen zur gemeinsamen verwendung für die weibliche kontrazeption
EP0877621A1 (de) Pharmazeutisches kombinationspräparat aus lhrh-analoga und antiöstrogenen zur behandlung von gynäcologischen störungen
DE69515666T2 (de) VERWENDUNG VON GnRH-ANTAGONISTEN ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR BEHANDLUNG GONADEN-STEROID ABHÄNGIGER ERKRANKUNGEN
DE69434239T2 (de) Verwendung eines Progesteronrezeptor-Antagonisten zur Verhütung oder Hemmung der Befruchtung
DE4329344A1 (de) Progesteronantagonistisch- und antiöstrogen wirksame Verbindungen für die Behandlung des Leiomyomata uteri
Balmaceda et al. The effects of chronic administration of LH-RH agonists and antagonists on the menstrual cycle and endometrium of the rhesus monkey
DE4216004B4 (de) Verwendung kompetitiver Progesteronantagonisten
EP0814803B1 (de) Verwendung von steroidalen Estrogenrezeptorantagonisten zur männlichen Fertilitätskontrolle
EP0214924B1 (de) Oxytocin und Antigestagen zur Einleitung der Geburt
EP0296097B1 (de) Arzneimittel enthaltend Progesteronsynthesehemmer vom Typ des Trilostans oder Epostans und Antigestagene
Monroe et al. Clinical investigations of the contraceptive and therapeutic potential of nafarelin
DE4406915A1 (de) Ovulationshemmendes Mittel zur hormonalen Kontrazeption
WO1996029078A1 (de) OVULATIONSHEMMENDES MITTEL ZUR HORMONALEN KONTRAZEPTION DAS 50-70 νg LEVONORGESTREL UND MEHR ALS 30-40 νg ETHINYLESTRADIOL ENTHÄLT

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee